(DOMS)
The reduced food intake, appetite and hunger satiety effects of GLP-1 agonists often result in weight loss
The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times, and some state Medicaid programs have begun covering GLP-1 agonists for obesity
This can support healthy blood sugar levels, slow down digestion, and reduce hunger, says Simran Malhotra, MD, DipABLM, CHWC, founder of Wellness By LifestyleMD in Bethesda, Maryland
Lilly submitted the diabetes NDA in October 2021, the FDA approved Mounjaro in May 2022, and the obesity approval (Zepbound) followed in November 2023
GLP-1 drugs do not work alone While the drugs can promote weight loss, they generally are not considered a standalone treatment for obesity